This module uses fundamental data of Mereo BioPharma to approximate its Piotroski F score. Mereo BioPharma F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of Mereo BioPharma Group. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about Mereo BioPharma financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Mereo BioPharma Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Mereo
Piotroski F Score
Change In Cash
Net Borrowings
Total Cashflows From Investing Activities
Other Cashflows From Financing Activities
Depreciation
Capital Expenditures
Total Cash From Operating Activities
Change To Account Receivables
Net Income
Total Cash From Financing Activities
Other Cashflows From Investing Activities
Change To Netincome
Change To Liabilities
Other Current Liab
Total Current Liabilities
Other Liab
Net Tangible Assets
Retained Earnings
Accounts Payable
Net Receivables
Other Current Assets
Other Stockholder Equity
Total Current Assets
Common Stock
Property Plant Equipment
Ebit
Net Income Applicable To Common Shares
Income Tax Expense
Probability Of Bankruptcy
At this time, it appears that Mereo BioPharma's Piotroski F Score is Inapplicable. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
The critical factor to consider when applying the Piotroski F Score to Mereo BioPharma is to make sure Mereo is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Mereo BioPharma's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Mereo BioPharma's financial numbers are properly reported.
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Mereo BioPharma's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Mereo BioPharma in a much-optimized way.
F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.
Net Tangible Assets
45.59 Million
At this time, Mereo BioPharma's Net Tangible Assets are comparatively stable compared to the past year.
About Mereo BioPharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Mereo BioPharma Group's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Mereo BioPharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Mereo BioPharma Group based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When running Mereo BioPharma's price analysis, check to measure Mereo BioPharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mereo BioPharma is operating at the current time. Most of Mereo BioPharma's value examination focuses on studying past and present price action to predict the probability of Mereo BioPharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mereo BioPharma's price. Additionally, you may evaluate how the addition of Mereo BioPharma to your portfolios can decrease your overall portfolio volatility.